{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:39:05Z","timestamp":1790908745546,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kyowa Kirin"},{"name":"Kyowa Kirin"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tumor-induced osteomalacia (TIO) is an ultra-rare disease caused mostly by benign tumors that secrete fibroblast growth factor-23. Because of nonspecific symptoms, the diagnostic delay is long, and therapy can be challenging. Moreover, epidemiological data on TIO are scarce owing to its rarity. Therefore, this study aimed to quantify TIO\u2019s incidence rates and prevalence in Germany. Retrospective longitudinal and cross-sectional analyses were conducted using anonymized German claims data from the statutory health insurance (SHI) database. This database, which comprises the data of approximately 5 million insurants, is a representative sample of the German population and supports national projections. As there is no unique International Statistical Classification of Diseases and Related Health Problems (ICD) code for TIO, operational categories based on different surrogates were defined to determine the prevalence and incidence rates of TIO among probable patients. This study showed that TIO has a prevalence of (documented code, advanced imaging, medication, or tumor removal) 0.187 per 100,000 persons and an incidence rate of\u2009\u2264\u20090.094 per 100,000 person years. This analysis provides the first epidemiological insight into German patients with TIO. Despite the general limitations associated with the analysis of SHI claims data of ultra-rare diseases, we believe that this analysis provides a sound basis for further analysis, particularly with regard to the care situation of patients with TIO.<\/jats:p>","DOI":"10.1007\/s00223-023-01148-2","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T14:02:46Z","timestamp":1700316166000},"page":"630-639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Epidemiology of Tumor-Induced Osteomalacia in Germany Based on Real World Data"],"prefix":"10.1007","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3910-773X","authenticated-orcid":false,"given":"Melanie","family":"May","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Oheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonore","family":"Bovy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Doess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Maessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benno","family":"Neukirch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raeleesha","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Abrahamsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,18]]},"reference":[{"issue":"3","key":"1148_CR1","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1530\/ERC-11-0006","volume":"18","author":"WH Chong","year":"2011","unstructured":"Chong WH, Molinolo AA, Chen CC, Collins MT (2011) Tumor-induced osteomalacia. Endocr Relat Cancer 18(3):R53-77","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"1148_CR2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s00223-020-00691-6","volume":"108","author":"P Florenzano","year":"2021","unstructured":"Florenzano P, Hartley IR, Jimenez M, Roszko K, Gafni RI, Collins MT (2021) Tumor-induced osteomalacia. Calcif Tissue Int 108(1):128\u2013142","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"1148_CR3","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/1097-0142(19870415)59:8<1442::AID-CNCR2820590810>3.0.CO;2-Q","volume":"59","author":"N Weidner","year":"1987","unstructured":"Weidner N, Santa Cruz D (1987) Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer 59(8):1442\u20131454","journal-title":"Cancer"},{"issue":"1","key":"1148_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000478-200401000-00001","volume":"28","author":"AL Folpe","year":"2004","unstructured":"Folpe AL, Fanburg-Smith JC, Billings SD et al (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28(1):1\u201330","journal-title":"Am J Surg Pathol"},{"issue":"7746","key":"1148_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0140-6736(72)92844-9","volume":"1","author":"DJ Evans","year":"1972","unstructured":"Evans DJ, Azzopardi JG (1972) Distinctive tumours of bone and soft tissue causing acquired vitamin-D-resistant osteomalacia. Lancet 1(7746):353\u2013354","journal-title":"Lancet"},{"key":"1148_CR6","doi-asserted-by":"publisher","first-page":"17044","DOI":"10.1038\/nrdp.2017.44","volume":"3","author":"S Minisola","year":"2017","unstructured":"Minisola S, Peacock M, Fukumoto S et al (2017) Tumour-induced osteomalacia. Nat Rev Dis Primers 3:17044","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"1148_CR7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00393-022-01160-1","volume":"81","author":"FT Beil","year":"2022","unstructured":"Beil FT, St\u00fcrznickel J, Rolvien T, Amling M, Oheim R (2022) Tumor localization and treatment of tumor-induced osteomalacia. Z Rheumatol 81(3):182\u2013188","journal-title":"Z Rheumatol"},{"issue":"3","key":"1148_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s00774-016-0756-9","volume":"35","author":"WJ Yu","year":"2017","unstructured":"Yu WJ, He JW, Fu WZ, Wang C, Zhang ZL (2017) Reports of 17 Chinese patients with tumor-induced osteomalacia. J Bone Miner Metab 35(3):298\u2013307","journal-title":"J Bone Miner Metab"},{"key":"1148_CR9","unstructured":"Minisola S, Fukumoto S, Xia W, et al (2022) Tumor-induced osteomalacia: a comprehensive Review [published online ahead of print, 2022 Nov 3].\u00a0Endocr Rev 2022:bnac026"},{"issue":"4","key":"1148_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00223-022-01005-8","volume":"111","author":"A Bosman","year":"2022","unstructured":"Bosman A, Palermo A, Vanderhulst J et al (2022) Tumor-induced osteomalacia: A systematic clinical review of 895 cases. Calcif Tissue Int 111(4):367\u2013379","journal-title":"Calcif Tissue Int"},{"key":"1148_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bonr.2017.09.002","volume":"7","author":"P Florenzano","year":"2017","unstructured":"Florenzano P, Gafni RI, Collins MT (2017) Tumor-induced osteomalacia. Bone Rep 7:90\u201397","journal-title":"Bone Rep"},{"issue":"4","key":"1148_CR12","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMc070347","volume":"357","author":"E Hesse","year":"2007","unstructured":"Hesse E, Rosenthal H, Bastian L (2007) Radiofrequency ablation of a tumor causing oncogenic osteomalacia. N Engl J Med 357(4):422\u2013424","journal-title":"N Engl J Med"},{"issue":"7","key":"1148_CR13","volume":"3","author":"SK Mishra","year":"2019","unstructured":"Mishra SK, Kuchay MS, Sen IB, Garg A, Baijal SS, Mithal A (2019) Successful management of tumor-induced osteomalacia with radiofrequency ablation: a case series. J Bone Mineral Res Plus 3(7):e10178","journal-title":"J Bone Mineral Res Plus"},{"issue":"6","key":"1148_CR14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s11926-015-0512-5","volume":"17","author":"AH Hautmann","year":"2015","unstructured":"Hautmann AH, Hautmann MG, K\u00f6lbl O, Herr W, Fleck M (2015) Tumor-induced osteomalacia: an up-to-date review. Curr Rheumatol Rep 17(6):512","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"1148_CR15","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1210\/jc.2013-2528","volume":"98","author":"VD Tarasova","year":"2013","unstructured":"Tarasova VD, Trepp-Carrasco AG, Thompson R et al (2013) Successful treatment of tumor-induced osteomalacia due to an intracranial tumor by fractionated stereotactic radiotherapy. J Clin Endocrinol Metab 98(11):4267\u20134272","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1148_CR16","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1210\/clinem\/dgac253","volume":"107","author":"D Rendina","year":"2022","unstructured":"Rendina D, Abate V, Cacace G et al (2022) Tumor-induced osteomalacia: a systematic review and individual Patient\u2019s data analysis. J Clin Endocrinol Metab 107(8):3428\u20133436","journal-title":"J Clin Endocrinol Metab"},{"key":"1148_CR17","unstructured":"European Commission; (2022). Union register of medicinal products for human use. CRYSVITA. https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h1262.htm. Accessed 13 July 2023"},{"issue":"2","key":"1148_CR18","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/jbmr.4184","volume":"36","author":"Y Imanishi","year":"2021","unstructured":"Imanishi Y, Ito N, Rhee Y et al (2021) Interim analysis of a Phase 2 open-label trial assessing burosumab efficacy and safety in patients with tumor-induced osteomalacia. J Bone Miner Res 36(2):262\u2013270","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1148_CR19","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jbmr.4233","volume":"36","author":"SM Jan de Beur","year":"2021","unstructured":"Jan de Beur SM, Miller PD, Weber TJ et al (2021) Burosumab for the treatment of tumor-induced osteomalacia. J Bone Miner Res 36(4):627\u2013635","journal-title":"J Bone Miner Res"},{"issue":"9","key":"1148_CR20","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","volume":"62","author":"I Endo","year":"2015","unstructured":"Endo I, Fukumoto S, Ozono K et al (2015) Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J 62(9):811\u2013816","journal-title":"Endocr J"},{"issue":"2","key":"1148_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00223-021-00843-2","volume":"109","author":"B Abrahamsen","year":"2021","unstructured":"Abrahamsen B, Smith CD, Minisola S (2021) Epidemiology of tumour-induced osteomalacia in Denmark. Calcif Tissue Int 109(2):147\u2013156","journal-title":"Calcif Tissue Int"},{"key":"1148_CR22","unstructured":"European Medicines Agency (EMA) (2018) Orphan Maintenance Assessment Report Crysvita (burosumab) Treatment of phosphaturic mesenchymal tumour. europa.eu. EMA\/179384\/2018) https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/18\/2011-public-summary-opinion-orphan-designation-burosumab-treatment-phosphaturic-mesenchymal-tumour_en.pdf. Accessed 13 July 2023"},{"key":"1148_CR23","unstructured":"Neubauer S, Zeidler J, Ansgar L, Von der Schulenburg JM (2014) Basic principles and methods of SHI routine data studies - Discussion Paper No. 534. Hannover: Leibniz Universit\u00e4t. Hanover: Faculty of Science"},{"key":"1148_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.puhe.2022.02.013","volume":"206","author":"M Ludwig","year":"2022","unstructured":"Ludwig M, Enders D, Basedow F, Walker J, Jacob J (2022) Sampling strategy, characteristics and representativeness of the InGef research database. Public Health 206:57\u201362","journal-title":"Public Health"},{"key":"1148_CR25","first-page":"120","volume-title":"Good practice secondary data analysis (GPS): guidelines and recommendations","author":"E Swart","year":"2015","unstructured":"Swart E et al (2015) Good practice secondary data analysis (GPS): guidelines and recommendations. Georg Thieme verlag KG, Health care, pp 120\u2013126"},{"issue":"8\u20139","key":"1148_CR26","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.zefq.2014.08.022","volume":"108","author":"E Swart","year":"2014","unstructured":"Swart E, Schmitt J (2014) STandardized Reporting Of Secondary data Analyses (STROSA)\u2014Vorschlag f\u00fcr ein Berichtsformat f\u00fcr Sekund\u00e4rdatenanalysen [STandardized Reporting Of Secondary data Analyses (STROSA)\u2014a recommendation]. Zeitschrift Evidenz Fortbildung Qualitat Gesundheitswesen 108(8\u20139):511\u2013516","journal-title":"Zeitschrift Evidenz Fortbildung Qualitat Gesundheitswesen"},{"key":"1148_CR27","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) (2022) Klassifikationen der Arzneimittel, ICD, OPS. https:\/\/www.dimdi.de\/dynamic\/de\/klassifikationen\/. Accessed 31 January 2023"},{"key":"1148_CR28","unstructured":"Kassenaerztliche Bundesvereinigung (KBV) (2022). EBM. https:\/\/www.kbv.de\/html\/online-ebm.php. Accessed 13 July 2023"},{"key":"1148_CR29","unstructured":"InEK. DRG catalogue (2019). https:\/\/www.g-drg.de\/Aktuelles\/Abrechnungsbestimmungen_und_DRG-Fallpauschalen-Katalog_2019 Accessed 31 January 2023"},{"issue":"1","key":"1148_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/pds.3895","volume":"25","author":"F Andersohn","year":"2016","unstructured":"Andersohn F, Walker J (2016) Characteristics and external validity of the German Health Risk Institute (HRI) Database. Pharmacoepidemiol Drug Saf 25(1):106\u2013109","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1148_CR31","unstructured":"Wissenschaftliches Institut der AOK (2020) Starker R\u00fcckgang der Krankenhaus-Fallzahlen durch coronavirus-Lockdown bei planbaren Eingriffen, aber auch bei Notf\u00e4llen. https:\/\/www.aok-bv.de\/presse\/pressemitteilungen\/2020\/index_23739.html. Accessed 13 July 2023"},{"key":"1148_CR32","unstructured":"Deutsches \u00c4rzteblatt (2020) \u00c4rzte appellieren, Arztbesuche nicht aufzuschieben. https:\/\/www.aerzteblatt.de\/nachrichten\/sw\/COVID-19?s=&p=1&n=1&nid=112413. Accessed 13 July 2023"},{"key":"1148_CR33","first-page":"1","volume":"5","author":"C Scheidt-Nave","year":"2020","unstructured":"Scheidt-Nave C, Barnes B, Beyer AK et al (2020) Care of the chronically ill in Germany: challenges in times of the COVID-19 pandemic. J health Monit 5:1\u201328","journal-title":"J health Monit"},{"issue":"1","key":"1148_CR34","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.jval.2021.11.197","volume":"25","author":"A Mevius","year":"2022","unstructured":"Mevius A, M\u00fcller S, Wilke T, Maywald U (2022) POSA52 A year-on-year comparison overall German healthcare resource utilization in COVID versus Non COVID times: a German claims data analysis. Value Health 25(1):S43","journal-title":"Value Health"},{"key":"1148_CR35","unstructured":"Orphanet (2022) Definition of osteomalacia, oncogenic. https:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?lng=DE&Expert=352540. Accessed 13 July 2023"},{"key":"1148_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116064","volume":"152","author":"ML Brandi","year":"2021","unstructured":"Brandi ML, Clunie GPR, Houillier P et al (2021) Challenges in the management of tumor-induced osteomalacia (TIO). Bone 152:116064","journal-title":"Bone"},{"key":"1148_CR37","unstructured":"Destatis Federal Statistical Office (2020) Population in Germany increased to 83.2 million in 2019. https:\/\/ww.destatis.de\/DE\/Presse\/Pressemitteilungen\/2020\/06\/PD20_223_12411.html. Accessed 31 March 2023"},{"key":"1148_CR38","unstructured":"R Core Team (2020). R: A language and environment for statistical computing www.r-project.org. Vienna, Austria: R Foundation for Statistical Computing. Accessed 01 August 2023"},{"key":"1148_CR39","unstructured":"Destatis, der Arbeit Q (2022) Krankenstand htt:\/\/www.destatis.de\/DE\/Themen\/Arbeit\/Arbeitsmarkt\/Qualitaet-Arbeit\/Dimension-2\/krankenstand.html. Statistisches Bundesamt. p. 11. Accessed 13 July 2023"},{"key":"1148_CR40","unstructured":"TK (2019) Gesundheitsreport. Arzneiverordnungen. tk.de. https:\/\/www.tk.de\/resource\/blob\/2062526\/b1ce85547f0622866b61a0843ced0bf0\/gesundheitsreport-arzneimittelverordnungen-2019-data.pdf. Accessed 13 July 2023"},{"key":"1148_CR41","unstructured":"BfArM (2023) Kodiersysteme\u2013 alpha-ID. https:\/\/www.bfarm.de\/DE\/Kodiersysteme\/Terminologien\/Alpha-ID-SE\/_node.html. Accessed 13 July 2023"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-023-01148-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-023-01148-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-023-01148-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T08:03:35Z","timestamp":1700813015000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-023-01148-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,18]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1148"],"URL":"https:\/\/doi.org\/10.1007\/s00223-023-01148-2","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,18]]},"assertion":[{"value":"13 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BA received grants (institutional contracts) from UCB and Novartis, consulting fees from UCB and Kyowa Kirin and personal fess (educational) from Amgen, Eli Lilly, Gedeon Richter, Pharmacosmos and UCB. RO received grants (institutional research contracts) from Kyowa Kirin and UCB, consulting fees from Ipsen Pharma, Kyowa Kirin, Pharmacosmos and personal fees (advisory boards, speaker, educational) from Inozyme, Ipsen, Kyowa Kirin, Pharmacosmos and UCB. This study was funded by Kyowa Kirin GmbH. BA, RO, and BN received personal consulting fees from Kyowa Kirin for creating the study design, reviewing the analysis protocol and code list, interpreting data, and contributing to and reviewing the manuscript. MM, DM, AD, and AW are employees of Kyowa Kirin. RN and LB are employees of the vendor InGef, Institute for Applied Health Research Berlin GmbH (InGef), which was contracted and reimbursed by the Hochschule Niederrhein, University of Applied Sciences to provide the data and carry out the analyses.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}